An observational study in Glycogen Storage Disease, GSD Type 0A and GSD Type 0B, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 0 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Glycogen Storage Disease with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Glycogen Storage Disease · United States.
Among the 16 studies in Glycogen Storage Disease with a site in United States, this one is the only one that started in 2024, is one of 8 observational ones, and was the 13th registered.
36 studies on the registry are indexed under Glycogen Storage Disease; 13 are open to participants now.
Browse Glycogen Storage Disease studies →5 of the 16 studies in Glycogen Storage Disease with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
AskBio Inc · Sites in United States
Ages 18–65
Shionogi · Sites in United States, Belgium, Denmark and 6 more countries
Ages 18+
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Glycogen Storage Disease studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6
First in 1992; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 200 is above the median of 85 across 16 observational studies indexed under Glycogen Storage Disease.
Median enrollment 14 across the 8 interventional studies, 45 across the 8 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 3 studies filed under Glycogen Storage Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Glycogen Storage Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05095727ModernaTX, Inc.A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | 2026-11-30 |
| NCT07123155ShionogiStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | 2027-08-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Glycogen Storage Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect and study key medical data about several ultra-rare GSDs (Glycogen Storage Diseases) including, but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease.
The immediate goal of this research is to create a natural history database to collect information from individuals who have a rare GSD. A repository of clinical, laboratory, and biochemical information on individuals with a rare GSD will allow a more definitive description of the different subtypes to be developed, which will permit development of treatment strategies in the future.
Duke will be the only site where this study takes place. However, since these are rare disorders, participants who receive care at other institutions will be included. The investigators will collect retrospective data from patient charts on diagnosed individuals, as far back as necessary to capture the clinical course of their disorder. Prospective data collected from patient charts after enrollment will be captured as well. Participant's medical records will be continually reviewed for the duration of the study.
Data will be collected from medical records and will only pertain to clinically relevant information, including, but not limited to: demographic and diagnostic information, tissue biopsy results, medical and family history, review of systems, imaging studies, results of liver, muscle, and nerve function testing, and urine and blood laboratory results.
All patients with rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease regardless of gender or ethnicity, are eligible for enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of a rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome or Danon disease
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
individuals with confirmed diagnosis of rare glycogen storage disease including but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease
Other: No intervention
Observational. Natural history study.
Progression of disease confirmed by medical record review
Time frame: through study completion, an average of 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2034, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.